Occurring in approximately 1 in 100,000 to 1 in 170,000 male births, Hunter Syndrome, is an X-linked disorder, of carbohydrate metabolism that occurs almost exclusively in males, with females as the carriers of the diseases.
The HunterSyndrome Market is expected to experience a positive push in the coming years with a CAGR of 7.5% for 7MM.
The key players in the Hunter Syndrome Market include JCR Pharmaceuticals Co Ltd, REGENXBIO Inc., GC Pharma, Denali Therapeutics, Sangamo Therapeutics, Inc., ArmaGen, Inc. and others.
For more details visit:
https://www.delveinsight.com/blog/hunter-syndrome-market/